Phase 3 Readout

ATRA: Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic

Name: Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic
Start: 2030-08-01
End: 2030-08-01

August 1, 2030 · tabelecleucel. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: August 1, 2030
Company: Atara Biotherapeutics, Inc. (ATRA)
Drug: tabelecleucel

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic

August 1, 2030

ATRA overview →

Company: Atara Biotherapeutics, Inc. (ATRA)
Drug: tabelecleucel
Indication: Solid Organ Transplant Complications; Lymphoproliferative Disorders; Allogeneic Hematopoietic Cell Transplant